Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has increased by over 3%, currently trading at HKD 9.15 with a transaction volume of HKD 297 million, following the acceptance of its application for the listing of empagliflozin tablets by the China National Medical Products Administration (NMPA) [1]. Group 1: Company Developments - CSPC Pharmaceutical's wholly-owned subsidiary, CSPC Ouyi Pharmaceutical Co., Ltd., has had its application for empagliflozin tablets accepted under the category of chemical drug registration [1]. - Empagliflozin is an SGLT-2 inhibitor primarily used for the treatment of type 2 diabetes, heart failure, and chronic kidney disease [1]. Group 2: Market Performance - Empagliflozin, developed by Boehringer Ingelheim in collaboration with Eli Lilly, is recognized as one of the three major SGLT-2 inhibitors globally, noted for its unique glucose-lowering mechanism and protective effects on cardiovascular and renal health [1]. - The sales scale of empagliflozin tablets in China has rapidly expanded, achieving a milestone of RMB 1 billion in 2024, with a nearly 20% year-on-year growth projected for the first quarter of 2025 [1].
港股异动 | 石药集团(01093)涨超3% 恩格列净片上市申请获受理